Late phase II/III study of BYM338 in patients with sporadic inclusion body myositis (RESILIENT): Japanese cohort data

Madoka Mori-Yoshimura, Satoshi Yamashita, Naoki Suzuki, Masahisa Katsuno, Kenya Murata, Hiroyuki Nodera, Rie Teshima, Tatsumi Inamura, Ichizo Nishino, Masashi Aoki

Research output: Contribution to journalArticle

Abstract

A global, randomized, double-blind placebo-controlled study was conducted to confirm that BYM338 (bimagrumab), an anti-activin type II receptor antibody, improves motor function in patients with sporadic inclusion body myositis after 52 weeks' treatment consisting of intravenous administration every 4 weeks at doses of 10, 3, and 1 mg/kg. In a Japanese sub-population (20 patients in total, 5 per dose group), no significant differences in the change from baseline of the 6-minute walking distance at Week 52 (primary endpoint) were observed between the placebo group and each BYM338 dose group. Furthermore, the lean body mass as an indicator of skeletal muscle mass increased in all BYM338 groups compared with the placebo group and the effects were dose-dependent. Overall, the Japanese sub-population showed similar trends as observed in the entire population (251 patients in total).

Original languageEnglish
Pages (from-to)806-813
Number of pages8
JournalClinical Neurology
Volume59
Issue number12
DOIs
Publication statusPublished - 2019 Jan 1

Keywords

  • Activin type II receptor
  • BYM338
  • Bimagrumab
  • Phase III
  • Sporadic inclusion body myositis

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Late phase II/III study of BYM338 in patients with sporadic inclusion body myositis (RESILIENT): Japanese cohort data'. Together they form a unique fingerprint.

  • Cite this

    Mori-Yoshimura, M., Yamashita, S., Suzuki, N., Katsuno, M., Murata, K., Nodera, H., Teshima, R., Inamura, T., Nishino, I., & Aoki, M. (2019). Late phase II/III study of BYM338 in patients with sporadic inclusion body myositis (RESILIENT): Japanese cohort data. Clinical Neurology, 59(12), 806-813. https://doi.org/10.5692/clinicalneurol.cn-001325